|

Type 1 Diabetes Recurrence in Pancreas Transplants

RECRUITINGSponsored by University of Miami
Actively Recruiting
SponsorUniversity of Miami
Started2005-05
Est. completion2026-05
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT01047865

Summary

The hypothesis is that humoral and cellular islet-specific responses are an early risk factor for recurrence of autoimmunity and hyperglycemia in simultaneous pancreas-kidney (SPK) recipients independent of alloimmunity. This study will test the hypothesis and will assess their individual and combined predictive value.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patient has been fully informed and has signed a dated IRB approval informed consent form and is willing to follow study procedures for the extent of the study (24 months). Parent or legal guardian must provide written consent for patients \<18 years of age.
* Age 18-75 years.
* Recipient of simultaneous pancreas and kidney transplant
* Primary or secondary renal allograft: living or deceased

Exclusion Criteria:

* Patient has previously received or is receiving an organ transplant other than a pancreas-kidney.

Conditions2

DiabetesDiabetes Mellitus, Type 1

Locations1 site

University of Miami Miller School of Medicine Transplant Clinic
Miami, Florida, 33136
George Burke, M.D.

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.